Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077102 | 1.00 | CYP1A2 (0.58) | CYP1A2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL10995247 | 0.83 | CYP1A2 (0.47) | CYP1A2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL10995248 | 0.83 | CYP1A2 (0.47) | CYP1A2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL28347012 | 0.82 | CYP1A2 (0.75) | CYP1A2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL30814554 | 0.82 | GSK3B (0.69) | CYP1A2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL17157605 | 0.82 | MAOB (0.54) | CYP1A2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL17157604 | 0.82 | MAOB (0.54) | CYP1A2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL10995524 | 0.82 | ALDH1A1 (0.51) | CYP1A2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL10995520 | 0.82 | ALDH1A1 (0.51) | CYP1A2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL2705827 | 0.81 | ALDH1A1 (0.57) | CYP1A2MAOBMAOAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586218-A | Chiral octacyclic ether compound and synthetic method and application thereof | 浙江工业大学 | 2024-02-23 | — | — | CN | disclosed |
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARM INC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2003050105-A2 | CATALYTIC ASYMMETRIC SYNTHESIS OF OPTICALLY ACTIVE COMPOUNDS | CHEMINOVA A/S (DK) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | CYP1A2 1700/4885MAOB 989/4885MAOA 1303/4885 |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | CYP1A2 1700/4885MAOB 989/4885MAOA 1303/4885 |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | CYP1A2 1700/4885MAOB 989/4885MAOA 1303/4885 |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | CYP1A2 1700/4885MAOB 989/4885MAOA 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.